List of Excipients in Branded Drug DRIZALMA SPRINKLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	AMMONIA
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	ASCORBIC ACID
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	D&C YELLOW NO. 10
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	FD&C BLUE NO. 1
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	FD&C RED NO. 40
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	FERROSOFERRIC OXIDE
SUN PHARMACEUTICAL INDUSTRIES INC	DRIZALMA SPRINKLE	duloxetine	47335-616	GELATIN

Drizalma Sprinkle Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Drizalma Sprinkle is a duloxetine hydrochloride delayed-release capsule that uses enteric-coated pellets to enable administration by sprinkling the dose over applesauce. Its commercial differentiation comes primarily from drug delivery and patient usability, not from a new active ingredient. The product targets patients who have difficulty swallowing conventional duloxetine capsules, while its excipient system protects duloxetine from gastric degradation and controls release in the intestine. [1]

What is Drizalma Sprinkle and how does its formulation work?

Drizalma Sprinkle contains duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor. The product is approved in 20 mg, 30 mg, 40 mg, and 60 mg delayed-release capsule strengths. Approved uses include major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults. [1]

The capsule is opened and its contents are sprinkled over a small amount of applesauce. The patient must swallow the mixture immediately without chewing the pellets. The product should not be crushed because the delayed-release structure depends on the integrity of the coated pellets. [1]

What dosage-form problem does Drizalma Sprinkle address?

Conventional duloxetine products are delayed-release capsules that generally must be swallowed intact. Drizalma Sprinkle addresses a specific administration barrier:

• Dysphagia and pill-swallowing difficulty
• Older adults with reduced swallowing capacity
• Patients with medication aversion or poor adherence
• Patients who cannot swallow large capsules
• Caregivers administering oral medicine to patients with limited cooperation

The product does not eliminate the need for delayed release. It changes the administration format while preserving enteric protection.

What excipients are used in Drizalma Sprinkle?

Drizalma Sprinkle uses a multiparticulate pellet system. The FDA prescribing information identifies inactive ingredients associated with the capsule, pellet core, enteric coating, and capsule shell. The listed excipient categories include sugar spheres, hypromellose, talc, sucrose, titanium dioxide, gelatin, colorants, and enteric-coating materials. [1]

Formulation component	Likely function in Drizalma Sprinkle	Commercial or technical role
Sugar spheres	Inert pellet core	Provides a uniform substrate for drug layering
Hypromellose	Film-forming polymer and binder	Supports drug layering and coating uniformity
Sucrose	Pellet-core or drug-layer component	Helps form a stable multiparticulate core
Talc	Anti-tacking and processing aid	Improves coating performance during manufacture
Enteric polymer	Gastro-resistant coating	Prevents release in the stomach
Plasticizer	Improves coating flexibility	Reduces cracking and mechanical failure
Titanium dioxide	Opacifier and colorant	Controls capsule or coating appearance
Gelatin	Hard-capsule shell	Provides the immediate container for pellets
Approved colorants	Strength identification	Supports dose differentiation and branding

The exact quantitative composition and manufacturing parameters are not generally disclosed in the public prescribing information. Those details are likely controlled through the product’s chemistry, manufacturing, and controls documentation.

Why is the enteric-coating excipient system commercially important?

Duloxetine is acid-labile. Exposure to gastric acid can degrade the active ingredient and reduce the amount reaching the intestine. The enteric coating therefore performs a central therapeutic function rather than merely improving appearance or handling.

The coating system must balance several properties:

1. Resistance to gastric fluid.
2. Reliable dissolution at intestinal pH.
3. Mechanical integrity during encapsulation, transport, and sprinkling.
4. Compatibility with applesauce.
5. Low pellet agglomeration.
6. Reproducible dose release across strengths.

A multiparticulate system also distributes the dose across many pellets. That can reduce the consequences of a localized coating defect compared with a single coated tablet, although it increases manufacturing complexity.

What formulation attributes are difficult for generic competitors to reproduce?

A generic applicant can use a different excipient system if it demonstrates bioequivalence and meets relevant quality requirements. The commercial barrier is therefore not the mere presence of sugar spheres, hypromellose, or an enteric polymer. The stronger barrier is the integrated performance of:

• Pellet size distribution
• Drug-layer uniformity
• Enteric-coat weight gain
• Dissolution profile
• Acid resistance
• Moisture protection
• Capsule-opening performance
• Stability after exposure to ambient humidity
• Dose recovery from applesauce
• Resistance to chewing or accidental crushing

These attributes create formulation know-how and process-control barriers even where the individual excipients are widely available.

What commercial opportunity does the sprinkle formulation create?

Drizalma Sprinkle occupies a dosage-form niche inside a mature duloxetine market. Generic duloxetine capsules are widely available and compete mainly on price. Drizalma Sprinkle can support a premium where the patient or caregiver values administration flexibility.

The main opportunity segments are:

Segment	Commercial rationale
Older adults	Higher prevalence of dysphagia and polypharmacy
Long-term-care residents	Caregiver-administered medication increases the value of flexible dosing
Patients with neurological disease	Swallowing impairment can limit use of intact capsules
Patients with psychiatric illness	Poor adherence and refusal of conventional dosage forms create a usability need
Pain patients	Chronic therapy increases the financial impact of missed doses
Specialty pharmacies	Formulation-specific counseling supports differentiated dispensing
Hospital discharge programs	Easier administration may reduce medication-management friction

The product is most defensible where the prescriber identifies a swallowing or administration problem. It is less defensible in price-sensitive patients who can take standard duloxetine capsules without difficulty.

How does Drizalma Sprinkle compare with generic duloxetine?

Attribute	Drizalma Sprinkle	Conventional generic duloxetine
Active ingredient	Duloxetine hydrochloride	Duloxetine hydrochloride
Release type	Delayed release	Delayed release
Administration	Capsule contents may be sprinkled on applesauce	Usually swallowed as an intact capsule
Patient usability	Better for selected swallowing-difficulty patients	Better for patients able to swallow capsules
Manufacturing complexity	Multiparticulate pellet system	Capsule or pellet-based systems vary
Price position	Potential branded premium	Low-cost generic
Differentiation	Administration method and product design	Price, supply, and pharmacy availability
Substitution risk	High where no administration barrier exists	High in routine adult use

Drizalma Sprinkle does not compete against generic duloxetine across the entire market on equal terms. It competes for patients for whom the conventional dosage form is inconvenient, impractical, or poorly tolerated from an administration standpoint.

What FDA regulatory status applies to Drizalma Sprinkle?

Drizalma Sprinkle received FDA approval in 2018 under an abbreviated regulatory pathway for a duloxetine delayed-release product. The FDA-approved labeling establishes the product’s indications, strengths, administration instructions, warnings, and inactive ingredients. [1]

The product’s regulatory value rests on several elements:

• Approved delayed-release performance
• A defined sprinkle administration method
• Stability of the pellet system
• Dose uniformity across four strengths
• Compatibility with the specified food vehicle
• Label-based instructions prohibiting chewing or crushing

The product is not a biologic, so biosimilar risk does not apply. Competitive risk comes from generic applicants, alternative duloxetine dosage forms, and products that obtain approval for comparable sprinkle administration.

What patents protect Drizalma Sprinkle?

Protection for Drizalma Sprinkle can arise from several patent categories:

1. Composition patents covering the duloxetine pellet formulation.
2. Process patents covering drug layering, enteric coating, or capsule filling.
3. Pharmaceutical composition patents covering the multiparticulate dosage form.
4. Method-of-use patents covering administration to patients unable to swallow intact capsules.
5. Regulatory exclusivity and other FDA protections associated with the approved application.

Patent scope must be separated from regulatory listing status. A patent may cover a manufacturing process or formulation without blocking every duloxetine product. Conversely, a listed drug product patent may create a Paragraph IV litigation pathway for an abbreviated new drug application.

The FDA Orange Book is the controlling public source for current listed patents and exclusivity information. [2] A current Orange Book review should identify whether any formulation or method-of-use patents remain listed for the relevant NDA, their expiration dates, and whether any pediatric or other regulatory exclusivity remains active.

When does Drizalma Sprinkle lose exclusivity?

The relevant loss-of-exclusivity date depends on the interaction of:

• Orange Book-listed patent expiration dates
• Any patent-term extension
• FDA regulatory exclusivity
• Paragraph IV certifications
• Litigation-related stays
• Settlement agreements
• The timing of final ANDA approval

Duloxetine as an active ingredient has long faced generic competition. The commercial question is therefore whether the specific sprinkle dosage form retains enforceable formulation or use protection, not whether duloxetine itself remains protected.

An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. A timely patent-infringement action can trigger an FDA approval stay of up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions and court developments. [3]

Which companies are challenging Drizalma Sprinkle?

Public competitive pressure is expected from generic manufacturers with existing duloxetine capabilities, including companies that already manufacture delayed-release duloxetine capsules. Likely competitors include large generic pharmaceutical companies and contract manufacturers with:

• Enteric-pellet manufacturing capacity
• Delayed-release dissolution testing
• Capsule-filling equipment
• FDA-approved duloxetine facilities
• Established pharmacy distribution

A company does not need to copy the brand’s excipients exactly. It needs to develop a bioequivalent delayed-release product and satisfy FDA requirements. The main competitive filter is formulation reproducibility, not ingredient scarcity.

No biosimilar pathway applies because duloxetine is a small-molecule drug.

What litigation and settlement issues affect the product?

Relevant litigation questions include:

• Whether the Orange Book lists formulation patents for the sprinkle product
• Whether an ANDA applicant filed a Paragraph IV certification
• Whether the sponsor sued within the statutory period
• Whether a 30-month stay applies
• Whether a court found a listed patent valid and infringed
• Whether the parties entered a license or launch-date settlement
• Whether an authorized generic or licensed generic agreement exists

A settlement can materially change the launch timeline without invalidating the underlying patent. Its commercial effects depend on the agreed entry date, permitted dosage strengths, authorized-generic rights, and supply obligations.

How strong is the patent estate for Drizalma Sprinkle?

The patent estate is strongest when it covers product-specific performance rather than generic excipient categories. Claims directed broadly to hypromellose, talc, sugar spheres, or enteric polymers are vulnerable because those materials are conventional pharmaceutical excipients.

Stronger claim concepts may include:

• Defined pellet architecture
• Specific coating thickness or weight-gain ranges
• Dissolution behavior across pH conditions
• Drug-loading uniformity
• Sprinkle administration with a specified food vehicle
• Stability under defined humidity and temperature conditions
• Manufacturing sequences that produce a distinctive release profile

The commercial strength of the estate also depends on claim breadth. Narrow process claims may deter some competitors but allow design-around formulations. Broader product claims can be more valuable if they survive validity challenges and cover commercially practical alternatives.

What excipient-based licensing opportunities exist?

Excipient technology can create licensing opportunities in five areas:

Enteric-coating platforms

A supplier with a robust acid-resistant coating system could license polymers, plasticizers, or coating processes for duloxetine and other acid-sensitive drugs.

Multiparticulate delivery

Pelletized products can be adapted for antidepressants, stimulants, proton-pump inhibitors, and pain medicines where flexible administration is commercially valuable.

Sprinkle-compatible dosage forms

Food-compatible multiparticulates are relevant to pediatric, geriatric, neurologic, and long-term-care markets. The principal opportunity is a platform that maintains dose uniformity after opening, mixing, and swallowing.

Taste and mouthfeel control

Patients may chew pellets despite label instructions. Taste-masking and reduced grittiness could improve adherence and create a formulation improvement opportunity.

Excipient substitution

Alternatives to gelatin, titanium dioxide, or certain colorants may support products designed for regional regulatory requirements, vegetarian positioning, or supply-chain resilience.

What manufacturing and IP barriers affect commercial expansion?

The main barriers are process-related:

• Uniform drug layering on starter spheres
• Consistent enteric coating across all pellets
• Prevention of pellet agglomeration
• Control of residual solvents and moisture
• Capsule filling at commercial scale
• Stability in high-humidity markets
• Dose recovery when the capsule is opened
• Validation of dissolution after food mixing

Manufacturers with existing delayed-release pellet infrastructure have a cost advantage. A company starting from a conventional capsule platform may require new fluid-bed coating equipment, analytical methods, stability programs, and operator training.

Geographic expansion also requires review of local rules for excipient use, capsule-shell composition, colorants, food vehicles, and product labeling. FDA approval does not automatically establish approval in Europe, Canada, Japan, or emerging markets.

What are the generic launch scenarios?

Three scenarios are commercially relevant:

Scenario	Market impact
No successful challenge before patent expiry	Brand retains the sprinkle niche until patent or exclusivity expiry
Single generic entrant	Moderate price erosion, with brand retention in dysphagia-focused segments
Multiple generic entrants	Rapid price compression and reduced pharmacy preference for the brand

A generic that offers the same sprinkle administration method could erode the product more quickly than a conventional duloxetine generic. A conventional capsule generic remains a substitute, but it does not fully replicate the product’s usability proposition.

Key Takeaways

• Drizalma Sprinkle is a duloxetine delayed-release pellet-in-capsule product approved in four strengths.
• Its principal differentiation is sprinkle administration over applesauce for patients who cannot swallow intact capsules.
• The excipient strategy depends on sugar-based pellet cores, film-forming materials, enteric protection, capsule-shell components, and colorants.
• The strongest technical barriers are coating integrity, dissolution control, dose uniformity, stability, and food-vehicle compatibility.
• The commercial opportunity is concentrated in dysphagia, geriatric, long-term-care, neurologic, psychiatric, and caregiver-administered settings.
• Generic risk is high for the active ingredient and conventional dosage form, but a product-specific formulation estate can delay or shape competition.
• Biosimilar risk does not apply because duloxetine is a small-molecule drug.
• Orange Book patents, Paragraph IV filings, litigation stays, and settlement terms determine the practical loss-of-exclusivity timeline.
• Excipient and multiparticulate technology can support licensing opportunities beyond duloxetine.

FAQs

Can Drizalma Sprinkle be mixed with water or juice?

The FDA labeling specifies sprinkling the capsule contents over applesauce and swallowing the mixture immediately. The labeled administration method should not be generalized to other vehicles. [1]

Can the pellets in Drizalma Sprinkle be crushed?

No. Crushing or chewing can disrupt the delayed-release coating and alter duloxetine exposure. [1]

Is Drizalma Sprinkle suitable for feeding-tube administration?

The prescribing information provides sprinkle-on-applesauce instructions, not a general feeding-tube administration claim. Tube use should not be inferred from the capsule-opening instructions.

Does Drizalma Sprinkle have a pediatric formulation opportunity?

The dosage form has potential relevance for pediatric drug delivery, but Drizalma Sprinkle’s approved indications and labeling are directed to adult treatment. A pediatric opportunity would require separate regulatory, palatability, dosing, and safety support.

Could a generic use different excipients from Drizalma Sprinkle?

Yes. An ANDA applicant generally may use a different excipient system if the product meets FDA requirements, including pharmaceutical equivalence, bioequivalence, quality, stability, and applicable labeling standards. The applicant does not necessarily need to duplicate the brand’s quantitative formulation. [3]

References

1. U.S. Food and Drug Administration. (2018). Drizalma Sprinkle (duloxetine hydrochloride) delayed-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). M13: Bioequivalence for immediate-release solid oral dosage forms. FDA.